Please assess the completion status of the following clinical trial:

Trial Title: Feasibility of Sentinel Lymph Node Biopsy in Rectal Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosed with operable rectal cancer~* case discussed at Oxford Colorectal Cancer multi-disciplinary team (MDT) meeting~* willing and able to give informed consent~* willing and able to comply with all trial requirements, in the investigator's opinion~Exclusion Criteria:~* females who are pregnant or lactating~* known intolerance or hypersensitivity to iron, dextran compounds, magnetic tracers or superparamagnetic iron oxide particles (SPIO)~* cancer involvement of anal sphincter complex~* adults who are not able to give consent or are deemed vulnerable

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Ex-vivo (Type: EXPERIMENTAL): Patients with relatively advanced rectal cancer who are scheduled to undergo radical surgery to excise rectal tumour and mesorectum. They will receive endoscopic Sienna+ injection (magnetic tracer) 5 days before planned surgery. They will then undergo surgery to excise rectal cancer. The excised specimen will be examined using the Sentimag probe and by standard histology to assess for lymph nodes ex-vivo.
- In-vivo (Type: EXPERIMENTAL): Patients with early rectal cancer scheduled to undergo local excision of a rectal tumour by transanal endoscopic microsurgery (TEM). They will receive endoscopic Sienna+ injection (magnetic tracer) 5 days before planned surgery, and have an MRI scan to assess tracer spread. They will then undergo TEM surgery to excise the rectal cancer. During surgery the Sentimag probe will be used to locate the sentinel lymph node so it can be surgically removed. The excised specimen will be examined by standard histology.

Based on this trial design, predict the completion outcome and termination type (if applicable).